U.S. Markets close in 2 hrs 30 mins
  • S&P 500

    4,411.08
    +43.60 (+1.00%)
     
  • Dow 30

    35,068.22
    +244.87 (+0.70%)
     
  • Nasdaq

    14,828.92
    +144.32 (+0.98%)
     
  • Russell 2000

    2,200.46
    +0.99 (+0.04%)
     
  • Crude Oil

    71.95
    +0.04 (+0.06%)
     
  • Gold

    1,802.20
    -3.20 (-0.18%)
     
  • Silver

    25.24
    -0.14 (-0.56%)
     
  • EUR/USD

    1.1777
    +0.0004 (+0.0353%)
     
  • 10-Yr Bond

    1.2860
    +0.0210 (+1.66%)
     
  • Vix

    17.27
    -0.42 (-2.37%)
     
  • GBP/USD

    1.3762
    -0.0006 (-0.0427%)
     
  • USD/JPY

    110.5200
    +0.4050 (+0.3678%)
     
  • BTC-USD

    32,145.35
    -264.54 (-0.82%)
     
  • CMC Crypto 200

    775.75
    -17.98 (-2.27%)
     
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • Nikkei 225

    27,548.00
    +159.80 (+0.58%)
     

AQST Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Aquestive Therapeutics, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 30, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ: AQST) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aquestive securities between December 2, 2019 and September 25, 2020, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/aqst.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, and failed to disclose that: (1) data included in the Libervant NDA submission showed a lower drug exposure level than desired for certain weight groups; (2) the foregoing significantly decreased the Libervant NDA's approval prospects; (3) as a result, it was foreseeable that the FDA would not approve the Libervant NDA in its current form; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/aqst or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Aquestive you have until April 30, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210430005002/en/

Contacts

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com